Tech Company Financing Transactions
Aptadir Therapeutics Funding Round
4BIO Capital, Angelini Ventures and CDP Venture Capital joined a $45 million Seed funding round for Aptadir Therapeutics. The round closed on 9/29/2026.
Transaction Overview
Company Name
Announced On
9/29/2026
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance its pipeline of disease-modifying investigational RNA therapeutics, including its lead candidate, CAP1-FMR1 for Fragile X Syndrome.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Via San Marco 21A
Milan, 20121
Italy
Milan, 20121
Italy
Phone
Undisclosed
Website
Email Address
Overview
We discovered a new class of specialized RNAs interacting with the mammalian DNMT1 -- DNMT1-interacting RNAs (DiRs). DiRs prevent DNA methylation and gene silencing in a locus-specific manner, by binding and inhibiting DNMT1 are able to reactivate suppressed genes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Giovanni Amabile
Browse more venture capital transactions:
Prev: 9/29/2026: Heaviside Industries venture capital transaction
Next: 9/29/2026: Elio Mortgage venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs